Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study

(2023) Luis Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer

(2023) Huan Zhang et al.   BIOMEDICINE & PHARMACOTHERAPY

CAR NK‐92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo

(2022) Manting Liu et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts

(2022) Rebecca Caeser et al.   Nature Communications

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology

(2022) Yanchen Zhou et al.   Journal for ImmunoTherapy of Cancer

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

(2022) L. Paz-Ares et al.   ESMO Open

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

(2022) Martin Wermke et al.   Future Oncology

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.

(2022) Melissa Lynne Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

(2022) Lihua E Budde et al.   LANCET ONCOLOGY

Teclistamab in Relapsed or Refractory Multiple Myeloma

(2022) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer

(2022) Anna Keogh et al.   Cancers

OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

(2022) C.M. Rudin et al.   Journal of Thoracic Oncology

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms

(2022) James Yao et al.   ONCOLOGIST

Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies

(2022) Tara Arvedson et al.   CURRENT OPINION IN BIOTECHNOLOGY

DLL3 regulates Notch signaling in small cell lung cancer

(2022) Jun W. Kim et al.   iScience

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

(2021) Carl M. Gay et al.   CANCER CELL

Small-cell lung cancer

(2021) Charles M. Rudin et al.   Nature Reviews Disease Primers

The PSMA Targeting Half-Life Extended BiTE® Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer

(2021) Petra Deegen et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

(2021) Fiona Blackhall et al.   Journal of Thoracic Oncology

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer

(2021) Jyoti Malhotra et al.   Journal of Thoracic Oncology

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

(2021) A.-M.C. Dingemans et al.   ANNALS OF ONCOLOGY

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

(2021) Zheng Tian et al.   Journal of Hematology & Oncology

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

(2021) Melissa L. Johnson et al.   Journal of Thoracic Oncology

Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies

(2021) Nga T. H. Truong et al.   Cancers

Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives

(2021) Lucia Anna Muscarella et al.   Cancers

1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)

(2021) A. Dowlati et al.   ANNALS OF ONCOLOGY

A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC

(2021) Christine L. Hann et al.   Journal of Thoracic Oncology

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

(2021) Wen‐Qian Li et al.   Cancer Medicine

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

(2021) Aaron S. Mansfield et al.   npj Precision Oncology

Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair

(2021) Barbara Rath et al.   ANTI-CANCER DRUGS

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

(2021) Apar Kishor P. Ganti et al.   Journal of the National Comprehensive Cancer Network

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma

(2021) Kirit Singh et al.   Journal for ImmunoTherapy of Cancer

Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples

(2021) Christiane Kuempers et al.   Frontiers in Medicine

SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

(2020) M. Dómine et al.   Clinical & Translational Oncology

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

(2020) José Trigo et al.   LANCET ONCOLOGY

A Bispecific DLL3/CD3 IgG-like T-cell Antibody induces anti-tumor responses in Small Cell Lung Cancer

(2020) Susanne Hipp et al.   CLINICAL CANCER RESEARCH

Breaking the Impasse

(2020) Andreas Saltos et al.   CLINICS IN CHEST MEDICINE

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study

(2020) Daniel Morgensztern et al.   LUNG CANCER

DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC

(2020) Hiroyuki Ogawa et al.   Thoracic Cancer

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth

(2020) Xin Chen et al.   Journal for ImmunoTherapy of Cancer

MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy

(2020) Annelisa M. Cornel et al.   Cancers

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer

(2020) Isabella Monia Montagner et al.   Cells

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

(2020) Andreas Viardot et al.   ANNALS OF HEMATOLOGY

Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization

(2020) Marina K. Baine et al.   Journal of Thoracic Oncology

International real-world study of DLL3 expression in patients with small cell lung cancer

(2020) Federico Rojo et al.   LUNG CANCER

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

(2020) Michael J. Giffin et al.   CLINICAL CANCER RESEARCH

TriTACs, a novel class of T cell-engaging protein constructs designed for the treatment of solid tumors

(2020) Richard J Austin et al.   MOLECULAR CANCER THERAPEUTICS

Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression

(2020) Philip Vitorino et al.   Translational Oncology

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

(2019) Loredana Puca et al.   Science Translational Medicine

DLL 3 regulates the migration and invasion of small cell lung cancer by modulating Snail

(2019) Megumi Furuta et al.   CANCER SCIENCE

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer

(2019) Jianling Huang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer

(2019) Yaru Tian et al.   Journal of Hematology & Oncology

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study

(2019) Daniel Morgensztern et al.   CLINICAL CANCER RESEARCH

Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment

(2019) Ippokratis Messaritakis et al.   LUNG CANCER

CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity

(2019) Ji Li et al.   Science Translational Medicine

Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer

(2019) Eva Obermayr et al.   Cells

Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events

(2019) Matthias Klinger et al.   CANCER RESEARCH

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

(2019) Brad S. Kahl et al.   CLINICAL CANCER RESEARCH

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

(2019) Neal E. Ready et al.   Journal of Thoracic Oncology

P1.12-18 Nonclinical Safety Assessment of AMG 757, a DLL3 Bispecific T Cell Engager, in the Cynomolgus Monkey

(2019) E. Lobenhofer et al.   Journal of Thoracic Oncology

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

(2019) Samuel J. Klempner et al.   ONCOLOGIST

DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile

(2019) B.C.M. Hermans et al.   LUNG CANCER

Treatment Options for Relapsed Small-Cell Lung Cancer: What Progress Have We Made?

(2018) Angel Qin et al.   Journal of Oncology Practice

Abstract 3814: TriTACs are novel T cell-engaging therapeutic proteins optimized for the treatment of solid tumors and for long serum half-life

(2018) Holger Wesche et al.   CANCER RESEARCH

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy

(2018) Sebastian Kobold et al.   Frontiers in Oncology

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target

(2018) Vadim S. Koshkin et al.   CLINICAL CANCER RESEARCH

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

(2018) Hao Xie et al.   Journal of Thoracic Oncology

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

(2017) Charles M Rudin et al.   LANCET ONCOLOGY

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

(2017) J Duell et al.   LEUKEMIA

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

(2017) E. Mejstríková et al.   Blood Cancer Journal

Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?

(2016) Hans-Peter Gerber et al.   BIOCHEMICAL PHARMACOLOGY

Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions

(2016) Matthias Klinger et al.   IMMUNOLOGICAL REVIEWS

ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

(2016) Mark D. Borromeo et al.   Cell Reports

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

(2015) Laura R. Saunders et al.   Science Translational Medicine

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

(2014) A. Augustyn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DARTs take aim at BiTEs

(2011) C. Rader   BLOOD

Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis

(2010) Gavin Chapman et al.   HUMAN MOLECULAR GENETICS

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY